Your browser doesn't support javascript.
loading
Small-Molecule Positive Allosteric Modulators of the ß2-Adrenoceptor Isolated from DNA-Encoded Libraries.
Ahn, Seungkirl; Pani, Biswaranjan; Kahsai, Alem W; Olsen, Eva K; Husemoen, Gitte; Vestergaard, Mikkel; Jin, Lei; Zhao, Shuai; Wingler, Laura M; Rambarat, Paula K; Simhal, Rishabh K; Xu, Thomas T; Sun, Lillian D; Shim, Paul J; Staus, Dean P; Huang, Li-Yin; Franch, Thomas; Chen, Xin; Lefkowitz, Robert J.
Affiliation
  • Ahn S; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Pani B; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Kahsai AW; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Olsen EK; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Husemoen G; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Vestergaard M; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Jin L; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Zhao S; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Wingler LM; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Rambarat PK; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Simhal RK; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Xu TT; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Sun LD; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Shim PJ; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Staus DP; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Huang LY; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Franch T; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Chen X; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
  • Lefkowitz RJ; Departments of Medicine (S.A., B.P., A.W.K., L.M.W., P.K.R., R.K.S., T.T.X., L.D.S., D.P.S., L.-Y.H., R.J.L.) and Biochemistry (R.J.L.) and Howard Hughes Medical Institute (L.M.W., D.P.S., R.J.L.), Duke University Medical Center, Durham, North Carolina; Nuevolution A/S, Copenhagen, Denmark (E.K.O.,
Mol Pharmacol ; 94(2): 850-861, 2018 08.
Article in En | MEDLINE | ID: mdl-29769246
ABSTRACT
Conventional drug discovery efforts at the ß2-adrenoceptor (ß2AR) have led to the development of ligands that bind almost exclusively to the receptor's hormone-binding orthosteric site. However, targeting the largely unexplored and evolutionarily unique allosteric sites has potential for developing more specific drugs with fewer side effects than orthosteric ligands. Using our recently developed approach for screening G protein-coupled receptors (GPCRs) with DNA-encoded small-molecule libraries, we have discovered and characterized the first ß2AR small-molecule positive allosteric modulators (PAMs)-compound (Cmpd)-6 [(R)-N-(4-amino-1-(4-(tert-butyl)phenyl)-4-oxobutan-2-yl)-5-(N-isopropyl-N-methylsulfamoyl)-2-((4-methoxyphenyl)thio)benzamide] and its analogs. We used purified human ß2ARs, occupied by a high-affinity agonist, for the affinity-based screening of over 500 million distinct library compounds, which yielded Cmpd-6. It exhibits a low micro-molar affinity for the agonist-occupied ß2AR and displays positive cooperativity with orthosteric agonists, thereby enhancing their binding to the receptor and ability to stabilize its active state. Cmpd-6 is cooperative with G protein and ß-arrestin1 (a.k.a. arrestin2) to stabilize high-affinity, agonist-bound active states of the ß2AR and potentiates downstream cAMP production and receptor recruitment of ß-arrestin2 (a.k.a. arrestin3). Cmpd-6 is specific for the ß2AR compared with the closely related ß1AR. Structure-activity studies of select Cmpd-6 analogs defined the chemical groups that are critical for its biologic activity. We thus introduce the first small-molecule PAMs for the ß2AR, which may serve as a lead molecule for the development of novel therapeutics. The approach described in this work establishes a broadly applicable proof-of-concept strategy for affinity-based discovery of small-molecule allosteric compounds targeting unique conformational states of GPCRs.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Receptors, Adrenergic, beta-2 / Small Molecule Libraries / Adrenergic beta-2 Receptor Agonists Language: En Year: 2018 Type: Article

Full text: 1 Database: MEDLINE Main subject: Receptors, Adrenergic, beta-2 / Small Molecule Libraries / Adrenergic beta-2 Receptor Agonists Language: En Year: 2018 Type: Article